| Expression pattern: |
UP |
| Associated gene: |
PD-L1 mRNA, IGF2BP3 |
| Associated microRNA: |
- |
| Biological function: |
Promotes breast cancer immune evasion and impairs CD8+ T cell-mediated antitumor immunity; enhances tumor growth/viability. |
| Molecular mechanism: |
circATAD2 binds PD-L1 mRNA and promotes IGF2BP3 recognition of m6A in PD-L1 3'-UTR, increasing PD-L1 mRNA stability and expression. |
| Biological pathway or process: |
immune regulation (inhibits); mRNA stability (promotes); other pathway/process (other) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; FISH / smFISH; Clinical Sample Validation; Survival Analysis; RIP (RNA Immunoprecipitation); MeRIP / MeRIP-seq; Luciferase Reporter Assay; Transfection; ELISA; Flow Cytometry（Non-apoptosis/cycle）; Western Blot; CCK8; EdU Staining; In Vivo Animal Model |
| Clinical significance: |
circATAD2 is upregulated in BC samples and closely correlated to poor prognosis; high circATAD2 shows lower overall survival rate. |
| Description: |
circATAD2 (hsa_circ_0085465) is upregulated in breast cancer and is associated with worse overall survival. It promotes immune evasion by binding PD-L1 mRNA and facilitating IGF2BP3-dependent recognition of m6A in the PD-L1 3'-UTR, thereby stabilizing PD-L1 mRNA and increasing PD-L1 expression, which reduces CD8+ T cell cytotoxicity. |
| Confidence score: |
0.8532 |